Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 41 citing articles:

Elacestrant in ER+, HER2– MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups
Aditya Bardia, Javier Cortés, François‐Clément Bidard, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 19, pp. 4299-4309
Open Access | Times Cited: 17
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 10, pp. 743-761
Closed Access | Times Cited: 11
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Rong Wang, Shiwei He, Jun Long, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer
Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, et al.
Drugs (2025)
Open Access | Times Cited: 1
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Jae Hyun Kim, et al.
(2025)
Open Access | Times Cited: 1
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Ana C. Garrido-Castro, Noah Graham, Lestat R. Ali, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010430-e010430
Open Access | Times Cited: 1
Current and future immunotherapy for breast cancer
Natalie K. Heater, Surbhi Warrior, Janice Lu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Nadia Ashai, Sandra M. Swain
Cancers (2023) Vol. 15, Iss. 6, pp. 1855-1855
Open Access | Times Cited: 12
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors
Carolina Reduzzi, Eleonora Nicolò, Surbhi Singhal, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 203, pp. 104483-104483
Closed Access | Times Cited: 4
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
Jessica Armand, Sungsoo Kim, Jae Hyun Kim, et al.
(2025)
Open Access
Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future.
Rosalba Torrisi, R. Gerosa, Chiara Miggiano, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104634-104634
Closed Access
Targeting CDK4/6 in breast cancer
Anusha Shanabag, Jessica Armand, Eugene Son, et al.
Experimental & Molecular Medicine (2025)
Open Access
Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?
Nanae Ogata, Brian Barnett, Nicholas Sharp, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 884-884
Open Access
Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast Cancer
Eudald Felip, Edurne García-Vidal, Sara Cabrero-de las Heras, et al.
Research Square (Research Square) (2025)
Closed Access
Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer
Taha Koray Şahin, Alessandro Rizzo, Deniz Can Güven, et al.
Cancer Treatment Reviews (2025), pp. 102924-102924
Closed Access
Mapping Breast Cancer Therapy with Circulating Tumor Cells: the expert perspective
Lorenzo Gerratana, Caterina Gianni, Eleonora Nicolò, et al.
The Breast (2025), pp. 104463-104463
Open Access
Novel Estrogen Receptor – Targeted Therapies in Hormone-Receptor Positive Breast Cancer
Nina E. Neill, Lauren Mauro, Angela Pennisi
Current Treatment Options in Oncology (2025)
Closed Access
Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer
Paola Ferrari, Maria B. Schiavone, Cristian Scatena, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3438-3438
Open Access
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer
Matthew P. Goetz, Seth A. Wander, Thomas Bachelot, et al.
Future Oncology (2025), pp. 1-8
Open Access
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer
Sudha Yarlagadda, Matheus de Oliveira Andrade, Rita Nanda
Expert Review of Anticancer Therapy (2025)
Closed Access
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial
Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló, et al.
Journal of Clinical Oncology (2025)
Closed Access
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights
Igor Makhlin, Lesley Fallowfield, N. Lynn Henry, et al.
JCO Oncology Practice (2024)
Closed Access | Times Cited: 2
Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer
Eugen Ruckhäberle, Marcus Schmidt, Anja Welt, et al.
Geburtshilfe und Frauenheilkunde (2024) Vol. 84, Iss. 09, pp. 813-836
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top